FDA orders boxed warning for Regranex
WASHINGTON (UPI) — The U.S. Food and Drug Administration announced the addition of a boxed warning for Regranex (becaplermin) because of an increased risk of cancer mortality. The warning includes updated epidemiological data about the increased risk for diabetic patients who use three or more tubes of the topical cream that’s indicated for the treatment […]
«« Read More Comments Off on FDA orders boxed warning for Regranex